OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results

OPKO reports a major asset sale, rising revenues, and ongoing clinical progress amid continued losses.

What the company is saying

OPKO Health, Inc. is emphasizing the signing of a definitive agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722 million in cash at closing, with up to $150 million in additional contingent payments over up to ten years based on Labcorp’s sales of the 4Kscore test. The company highlights the expansion of its financing relationship with HealthCare Royalty, raising $125 million through senior secured royalty notes tied to royalties from Eli Lilly’s mazdutide. OPKO details clinical progress, including dosing the first participant in a Phase 1/2a trial of OPK-8801001 for acromegaly, and ModeX’s completion of enrollment in the MDX2301 Phase 1 trial, with additional trials ongoing in Australia and Israel. The company presents its financial results with a focus on a 16% revenue increase in continuing operations to $65.4 million, improved Global Products segment performance, and a narrowed operating loss. OPKO also notes the reclassification of BioReference as discontinued operations and the withdrawal of certain financial guidance due to the pending Labcorp transaction. The tone is factual, with detailed segment disclosures and clear explanations for revenue changes, such as higher Lilly royalties, Rayaldee sales, and international growth.

What the data suggests

The agreement with Labcorp provides for $722 million in upfront cash, subject to closing adjustments, and up to $150 million in additional payments over a decade, but the transaction is not yet closed and remains subject to regulatory approvals. OPKO’s consolidated continuing operations revenue rose 16% year-over-year to $65.4 million, driven by increased Lilly royalty revenue, Rayaldee sales, and international operations, including a $0.7 million favorable FX impact. Global Products segment revenue increased to $48.4 million, with Rayaldee revenue up to $8.6 million and licensing, collaboration, and other revenue climbing to $6.6 million, primarily from $5.8 million in Lilly royalties. The Global Products segment swung to a $6.0 million operating income from a $1.2 million loss, while Innovative Biotech revenue was flat at $17.0 million and its operating loss widened to $26.8 million. R&D expense increased to $30.4 million, reflecting higher investment in ModeX programs. Net loss from continuing operations was $35.5 million, or $0.05 per share, compared to $33.0 million, or $0.04 per share, in the prior year. Cash, cash equivalents, and restricted cash stood at $403.2 million, bolstered by $123.1 million in royalty financing proceeds and $19.8 million from escrow release. OPKO repurchased 7,050,000 shares for $10.6 million, with $84.3 million remaining under its $200 million buyback authorization. BioReference, now classified as discontinued, saw revenue fall to $71.8 million with an $18.0 million net loss. The company withdrew guidance for services revenue and total costs due to uncertainty around the Labcorp deal’s timing.

Analysis

The announcement is comprehensive and factual, with most claims supported by specific financial and operational data. The tone is measured, and the majority of key developments—such as the Labcorp sale agreement, financing, and clinical trial milestones—are realised or in advanced stages, not merely aspirational. Forward-looking statements (e.g., pending regulatory approvals, future clinical data, and withdrawn guidance) are clearly identified and do not dominate the narrative. The company discloses both revenue and profitability metrics, including operating loss, segment income/loss, and net loss, allowing for a transparent assessment of financial health. While the Labcorp transaction involves a large capital sum and is not yet closed, the agreement is signed and the risks are appropriately caveated. There is no evidence of narrative inflation or exaggerated claims; language around clinical progress and financials is proportionate to the disclosed facts.

Risk flags

• ●The Labcorp sale, while contractually agreed, is subject to regulatory approvals and customary closing conditions; any delay or failure to close would materially impact OPKO’s cash position and strategic direction.
• ●The $150 million in additional Labcorp consideration is contingent on future sales of the 4Kscore test, introducing significant uncertainty both in timing and amount, as it depends on Labcorp’s commercial execution over a ten-year period.
• ●OPKO continues to report net losses from continuing operations ($35.5 million for Q3 2026), and while revenue is rising, profitability remains elusive, raising questions about the sustainability of operations post-transaction.
• ●The company has withdrawn guidance for services revenue and total costs and expenses due to uncertainty around the Labcorp transaction, reducing forward visibility for investors and complicating financial forecasting.
• ●Clinical pipeline progress is at an early stage, with key data readouts for several programs not expected until 2027, leaving substantial development and regulatory risk before any commercial value can be realized.

Bottom line

OPKO Health is in the midst of a major strategic shift, with a signed agreement to sell most of its BioReference diagnostics business to Labcorp for $722 million in cash, plus up to $150 million in long-term contingent payments. While core continuing operations revenue grew 16% to $65.4 million and the Global Products segment turned profitable, the company remains loss-making overall, posting a $35.5 million net loss from continuing operations in Q3 2026. Cash reserves are strong at $403.2 million, aided by new royalty financing and asset sale proceeds, and the company is actively buying back shares. However, the Labcorp transaction is not yet closed, and the timing and certainty of both the upfront and contingent payments remain at risk pending regulatory approvals. The clinical pipeline is advancing, but key data is not expected until 2027, so near-term operating results will depend on the successful closing of the Labcorp deal and disciplined cost management. Investors should focus on the progress toward closing the Labcorp transaction and watch for updates on clinical trial milestones and the company’s ability to stem ongoing losses.

Announcement summary

(NASDAQ:OPK) OPKO Health, Inc. reported business highlights and financial results for the third quarter ended September 30, 2026. OPKO entered into an agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations, with $722 million in cash consideration at closing, subject to adjustments, and up to $150 million in additional cash consideration over up to ten years based on Labcorp sales of the 4Kscore® test. The transaction is subject to regulatory approvals and customary closing conditions. OPKO expanded its strategic relationship with HealthCare Royalty through a $125 million financing, issuing an additional $125 million aggregate principal amount of senior secured royalty notes, with the amended framework including specified royalty payments receivable under OPKO’s license agreement with Eli Lilly and Company related to mazdutide. OPKO Biologics dosed the first participant in a Phase 1/2a trial of OPK-8801001 for acromegaly, designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic activity. ModeX completed enrollment in the MDX2301 Phase 1 clinical trial, funded by BARDA, and continues enrollment in MDX2001 and MDX2004 Phase 1 trials at sites in Australia and Israel, with initial data expected in the first half of 2027. ModeX is also enrolling patients in the MDX2003 Phase 1 clinical trial in relapsed or refractory B-cell lymphoma. OPKO continues U.S. enrollment in the Phase 1/2a study of OPK-88006, with favorable safety and tolerability observed in 3 dose levels in 24 participants. Following the Board’s September 30, 2026 approval of the BioReference sale plan, BioReference’s historical results are presented as discontinued operations. Consolidated continuing operations revenue in Q3 2026 increased 16% to $65.4 million from $56.4 million in Q3 2025, mainly due to higher royalty revenue from Lilly, increased Rayaldee sales, and growth in international operations. Operating loss in Q3 2026 decreased to $31.4 million from $33.6 million in Q3 2025. Non-cash depreciation, amortization, and equity-based compensation expense included in operating income (loss) was $20.7 million in Q3 2026 versus $20.5 million in Q3 2025. Net loss from continuing operations in Q3 2026 was $35.5 million, or $0.05 per share, compared to $33.0 million, or $0.04 per share, in Q3 2025. Global Products segment revenue for Q3 2026 increased to $48.4 million from $39.4 million in Q3 2025, with Rayaldee revenue rising to $8.6 million from $7.5 million. Revenue from international operations increased by approximately $3.0 million, including a $0.7 million favorable foreign currency impact. Licensing, collaboration, and other revenue for Q3 2026 increased to $6.6 million from $1.8 million, primarily driven by $5.8 million of royalty revenue from Lilly. Global Products segment operating income for Q3 2026 was $6.0 million compared to an operating loss of $1.2 million in Q3 2025. Innovative Biotech licensing, collaboration, and other revenue was $17.0 million in both Q3 2026 and Q3 2025. BARDA revenue in Q3 2026 was $7.5 million compared to $8.2 million in Q3 2025. Research and development expense for Q3 2026 increased to $30.4 million from $26.3 million in Q3 2025. Innovative Biotech segment operating loss in Q3 2026 was $26.8 million compared to $22.5 million in Q3 2025. Unallocated corporate operating loss in Q3 2026 was $10.6 million compared to $9.9 million in Q3 2025. BioReference generated revenue of $71.8 million in Q3 2026 compared to $95.2 million in Q3 2025, with a loss from discontinued operations, net of tax, of $18.0 million in Q3 2026 versus income of $54.6 million in Q3 2025. Cash, cash equivalents, and restricted cash were $403.2 million as of September 30, 2026. OPKO received approximately $123.1 million of net proceeds from the additional royalty financing and $19.8 million from the release of escrow funds related to the September 2025 oncology transaction. OPKO repurchased 7,050,000 shares during the quarter for approximately $10.6 million, with $115.7 million deployed under the $200 million share repurchase authorization, leaving $84.3 million available. OPKO has withdrawn previously issued guidance for services revenue and total costs and expenses due to uncertainty regarding the timing of the Labcorp transaction closing.

Disagree with this article?